Compare BUD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUD | VRTX |
|---|---|---|
| Founded | 1366 | 1989 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | EDP Services |
| Sector | Consumer Staples | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4B | 115.7B |
| IPO Year | N/A | 1991 |
| Metric | BUD | VRTX |
|---|---|---|
| Price | $68.82 | $448.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 27 |
| Target Price | $88.00 | ★ $501.42 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 02-25-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.00 | ★ 14.22 |
| Revenue | ★ $58,605,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $0.67 | $11.01 |
| Revenue Next Year | $5.43 | $8.74 |
| P/E Ratio | ★ $22.64 | $31.97 |
| Revenue Growth | N/A | ★ 10.33 |
| 52 Week Low | $45.94 | $362.50 |
| 52 Week High | $72.13 | $519.68 |
| Indicator | BUD | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.39 | 46.51 |
| Support Level | $63.14 | $443.12 |
| Resistance Level | $65.99 | $487.52 |
| Average True Range (ATR) | 0.84 | 9.79 |
| MACD | 0.42 | -1.88 |
| Stochastic Oscillator | 96.27 | 12.36 |
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.